nct_id,title,phase,status,study_type,conditions,interventions,molecular_targets,sponsor,collaborators,enrollment_count,start_date,completion_date,locations,needs_review,source_url
NCT02332668,"A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)",Phase 1/Phase 2,Recruiting,Interventional,Melanoma; Lymphoma; Solid Tumor; Classical Hodgkin Lymphoma; Microsatellite-instability-high Solid Tumor,Pembrolizumab,,Merck Sharp & Dohme LLC,,370,2015-03-18,2027-10-25,Brazil; France; Germany; Israel; Italy; Netherlands; Portugal; South Korea; Sweden; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT02332668
NCT02333604,Cancer Experience Registry: An Online Survey Research Study to Understand the Experiences of Cancer Patients and Caregivers,,Recruiting,Observational,Neoplasms; Cancer; Caregiver,,,"Cancer Support Community, Research and Training Institute, Philadelphia",,15000,2013-03-05,2035-12-05,United States,No,https://clinicaltrials.gov/study/NCT02333604
NCT02366819,PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma,Phase 4,Recruiting,Interventional,Esophageal Adenocarcinoma; Gastric Adenocarcinoma; Stage IIB Gastric Cancer; Stage IIIA Esophageal Adenocarcinoma; Stage IIIA Gastric Cancer; Stage IIIB Esophageal Adenocarcinoma; Stage IIIB Gastric Cancer; Stage IIIC Esophageal Adenocarcinoma; Stage IIIC Gastric Cancer,Oxaliplatin; Leucovorin Calcium; Irinotecan Hydrochloride; Fluorouracil; Conventional Surgery,,University of Chicago,National Cancer Institute (NCI),36,2014-12-11,2026-06-08,United States,No,https://clinicaltrials.gov/study/NCT02366819
NCT02693535,Targeted Agent and Profiling Utilization Registry (TAPUR) Study,Phase 2,Recruiting,Interventional,"Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors",Palbociclib; Sunitinib; Temsirolimus; Trastuzumab and Pertuzumab; Vemurafenib and Cobimetinib; Regorafenib; Olaparib; Pembrolizumab; Nivolumab and Ipilimumab; Abemaciclib; Talazoparib; Atezolizumab and PHESGO; Atezolizumab and Talazoparib; Entrectinib; Larotrectinib; Tucatinib plus Trastuzumab Subcutaneous (SC); Futibatinib,,American Society of Clinical Oncology,"AstraZeneca; Bayer; Bristol-Myers Squibb; Eli Lilly and Company; Genentech, Inc.; Merck Sharp & Dohme LLC; Pfizer; Boehringer Ingelheim; Seagen Inc.; Taiho Oncology, Inc.",4200,2016-03-14,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT02693535
NCT03607890,Phase 2 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor,Phase 2,Recruiting,Interventional,Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy; MSI-H Tumors,Nivolumab; Relatlimab; Nivolumab; Relatlimab; Nivolumab; Relatlimab,,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Bristol-Myers Squibb; National Cancer Institute (NCI),42,2018-11-16,2026-10-05,United States,No,https://clinicaltrials.gov/study/NCT03607890
NCT03723928,Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer,Not Applicable,Recruiting,Interventional,Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8; Elevated CA15-3 or CEA or CA27-29,Usual care disease monitoring; Serum Tumor Marker directed disease monitoring; Quality-of-Life Assessment; Anxiety Questionnaire Administration,,SWOG Cancer Research Network,National Cancer Institute (NCI),739,2018-09-17,2036-12-01,Guam; Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT03723928
NCT03740256,A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors,Phase 1,Recruiting,Interventional,Bladder Cancer; Head and Neck Squamous Cell Carcinoma; Cancer of the Salivary Gland; Lung Cancer; Breast Cancer; Gastric Cancer; Esophageal Cancer; Colorectal Cancer; Pancreatic Adenocarcinoma; Solid Tumor,CAdVEC,,Baylor College of Medicine,The Methodist Hospital Research Institute,45,2020-12-14,2038-12-30,United States,No,https://clinicaltrials.gov/study/NCT03740256
NCT03935893,A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers,Phase 2,Recruiting,Interventional,Gastric Cancer; Colorectal Cancer; Pancreatic Cancer; Sarcoma; Mesothelioma; Neuroendocrine Tumors; Squamous Cell Cancer; Merkel Cell Carcinoma; Mismatch Repair Deficiency; Microsatellite Instability,Tumor Infiltrating Lymphocytes (TIL); Fludarabine + Cyclophosphamide combination,,Udai Kammula,,240,2019-12-03,2038-06-30,United States,No,https://clinicaltrials.gov/study/NCT03935893
NCT04074720,Prospective Breast Cancer Biospecimen Collection,,Recruiting,Observational,Breast Cancer; Invasive Breast Cancer; Carcinoma in Situ of the Breast,Tissue Sample collection; Blood Sample Collection; Rectal Swab,,Thomas Jefferson University,,200,2018-05-10,2028-07-01,United States,No,https://clinicaltrials.gov/study/NCT04074720
NCT04107077,A Phase IIa Study of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and PD-L1 Expression in Gastric Cancer With Peritoneal Metastases,Phase 2,Recruiting,Interventional,Gastric Cancer; Peritoneal Carcinomatosis,Cisplatin; Mitomycin,,University of Chicago,,21,2025-09-09,2026-06-01,United States,No,https://clinicaltrials.gov/study/NCT04107077
NCT04114136,A Phase II Clinical Trial of Anti-PD-1 mAb Therapy Alone or With Metabolic Modulators to Reverse Tumor Hypoxia and Immune Dysfunction in Solid Tumor Malignancies,Phase 2,Recruiting,Interventional,Melanoma; NSCLC; Hepatocellular Carcinoma; Urothelial Cancer; Gastric Adenocarcinoma; HNSCC; Esophageal Adenocarcinoma; Microsatellite Instability-High Solid Malignant Tumor,Nivolumab or Pembrolizumab (dependent upon approved indication); Metformin; Rosiglitazone,,Dan Zandberg,,72,2020-09-14,2032-04-30,United States,No,https://clinicaltrials.gov/study/NCT04114136
NCT04130516,"A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab",Phase 1/Phase 2,Recruiting,Interventional,"Solid Tumor, Adult","LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER; Pembrolizumab - anti-PD-1 antibody",,"Linnaeus Therapeutics, Inc.",Merck Sharp & Dohme LLC,200,2019-10-21,2027-12-15,United States,No,https://clinicaltrials.gov/study/NCT04130516
NCT04221893,Phase II Study of Hypofractionated Radiation Therapy to Augment Immune Response in Patients With Metastatic GastroIntestinal Malignancies Progressing on Immune Therapy (ARM-GI),Not Applicable,Recruiting,Interventional,Stage IV Esophageal Adenocarcinoma; Stage IV Esophageal Squamous Cell Carcinoma; Stage IV Gastric Cancer; Stage IV Adenocarcinoma of the Gastroesophageal Junction; Stage IVA Esophageal Adenocarcinoma; Stage IVA Esophageal Squamous Cell Carcinoma; Stage IVA Gastric Cancer; Stage IVA Adenocarcinoma of the Gastroesophageal Junction; Stage IVB Esophageal Adenocarcinoma; Stage IVB Esophageal Squamous Cell Carcinoma; Stage IVB Gastric Cancer; Stage IVB Gastroesophageal Junction Adenocarcinoma; Metastatic Anal Canal Carcinoma; Metastatic Colorectal Carcinoma; Metastatic Esophageal Carcinoma; Metastatic Gastric Carcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Metastatic Hepatocellular Carcinoma; Metastatic Malignant Digestive System Neoplasm; Metastatic Small Intestinal Carcinoma; Pancreatobiliary Carcinoma; Pathologic Stage IV Gastric Cancer AJCC v8; Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8; Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC V8; Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Stage IV Anal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Stage IVC Colorectal Cancer AJCC v8,Radiation Therapy (RT),,"University of California, San Francisco",Varian Medical Systems,28,2020-08-07,2028-04-30,United States,No,https://clinicaltrials.gov/study/NCT04221893
NCT04383262,"A 12-Week Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy of Oral Fosamprenavir for Laryngopharyngeal Reflux",Phase 2,Not yet recruiting,Interventional,Laryngopharyngeal Reflux,Fosamprenavir Calcium; Placebo,,Medical College of Wisconsin,,104,2026-03-01,2027-10-01,United States,No,https://clinicaltrials.gov/study/NCT04383262
NCT04421820,A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy in Patients With Advanced Solid Tumours,Phase 1/Phase 2,Recruiting,Interventional,Colorectal Cancer; Pancreatic Cancer; Gastric Cancers; Cholangiocarcinoma,BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion); BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation),,"Bold Therapeutics, Inc.",,220,2020-08-28,2026-09-01,Canada; Ireland; South Korea; United States,No,https://clinicaltrials.gov/study/NCT04421820
NCT04486352,A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer,Phase 1/Phase 2,Recruiting,Interventional,Endometrial Cancer,Atezolizumab - 28 Day Cycle; Bevacizumab; Ipatasertib; Talazoparib; Trastuzumab emtansine; Tiragolumab; Atezolizumab - 21 Day Cycle; Inavolisib; Letrozole; Giredestrant; Abemaciclib,,"Alliance Foundation Trials, LLC.","Genentech, Inc.; Foundation Medicine; Pfizer; Eli Lilly and Company",148,2021-10-20,2027-10-05,United States,No,https://clinicaltrials.gov/study/NCT04486352
NCT04557969,"Prospective Study of Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis",,Recruiting,Observational,Gastric Cancer; Gastric Neoplasm; Gastrointestinal Stromal Sarcoma; Gastrointestinal Stromal Neoplasm; Gastrointestinal Stromal Tumor (GIST),,,National Cancer Institute (NCI),,400,2020-12-18,2040-12-30,United States,No,https://clinicaltrials.gov/study/NCT04557969
NCT04600466,Identification of Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer in High-risk Predominantly Hispanic Population,,Recruiting,Observational,Gastric Cancer,Molecular testing for all participants.; Germline Testing; Survey,,The University of Texas Health Science Center at San Antonio,IIMS-UT Health San Antonio; National Center for Advancing Translational Sciences (NCATS),150,2021-01-22,2030-01-22,United States,No,https://clinicaltrials.gov/study/NCT04600466
NCT04609592,"Pilot Phase 1 Study of Perioperative Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic, WHO Grade 1 or 2, SSTR Positive, Gastroenteropancreatic Neuroendocrine Tumors Who Are Candidates for Cytoreductive Surgery",Phase 1,Recruiting,Interventional,Gastroenteropancreatic Neuroendocrine Tumor,Lutathera; Gallium 68 Dotatate; Computed Tomography (CT); Magnetic Resonance Imaging (MRI); PET/CT,,Stanford University,Novartis Pharmaceuticals,10,2021-03-17,2027-09-05,United States,No,https://clinicaltrials.gov/study/NCT04609592
NCT04704661,Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial),Phase 1,Recruiting,Interventional,Advanced Breast Carcinoma; Advanced Colon Carcinoma; Advanced Colorectal Carcinoma; Advanced Endometrial Carcinoma; Advanced Gastric Carcinoma; Advanced Gastroesophageal Junction Adenocarcinoma; Advanced Malignant Solid Neoplasm; Advanced Salivary Gland Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; HER2-Positive Breast Carcinoma; Malignant Hepatobiliary Neoplasm; Metastatic Breast Carcinoma; Metastatic Colon Carcinoma; Metastatic Colorectal Carcinoma; Metastatic Endometrial Carcinoma; Metastatic Gastric Carcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Salivary Gland Carcinoma; Stage III Colon Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Major Salivary Gland Cancer AJCC v8; Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8; Stage IV Colon Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Major Salivary Gland Cancer AJCC v8; Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8; Unresectable Breast Carcinoma; Unresectable Colon Carcinoma; Unresectable Colorectal Carcinoma; Unresectable Endometrial Carcinoma; Unresectable Gastric Carcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma; Unresectable Malignant Solid Neoplasm; Unresectable Salivary Gland Carcinoma,Biopsy Procedure; Biospecimen Collection; Ceralasertib; Computed Tomography; Echocardiography Test; Multigated Acquisition Scan; Positron Emission Tomography; Trastuzumab Deruxtecan,,National Cancer Institute (NCI),,51,2021-08-09,2026-03-31,United States,No,https://clinicaltrials.gov/study/NCT04704661
NCT04774419,"Adjuvant Checkpoint Blockade Plus Radiation In Locally Advanced, Mismatch Repair Deficient/Microsatellite Instability-High (MMR-D/MSI-H) Endometrial Cancer",Phase 2,Recruiting,Interventional,Endometrial Cancer,Intensity modulated radiation therapy (IMRT); Dostarlimab; Hypofractionated IMRT,,Memorial Sloan Kettering Cancer Center,"Tesaro, Inc.",62,2021-04-02,2026-02-05,United States,No,https://clinicaltrials.gov/study/NCT04774419
NCT04777994,A Phase 1 Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors,Phase 1,Recruiting,Interventional,Advanced Solid Tumor Cancer,ABBV-CLS-484; Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI); Programmed Cell Death-1 (PD-1) Inhibitor,,Calico Life Sciences LLC,,248,2021-03-09,2026-10-05,France; Israel; Japan; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT04777994
NCT04787042,"A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 with or Without Obinutuzumab Pre-Treatment, and ST-067 in Combination with Pembrolizumab in Subjects with Advanced Solid Malignancies",Phase 1/Phase 2,Recruiting,Interventional,Cancer; Solid Tumor; Melanoma; Renal Cell Carcinoma; Triple-negative Breast Cancer; Non Small Cell Lung Cancer; Squamous Cell Carcinoma of the Head and Neck; Carcinoma; MSI-High,ST-067; Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]; pembrolizumab,,"Simcha IL-18, Inc.",Merck Sharp & Dohme LLC,316,2021-08-06,2025-12-31,United States,No,https://clinicaltrials.gov/study/NCT04787042
NCT04802759,"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER)",Phase 1/Phase 2,Recruiting,Interventional,"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer",Giredestrant; Abemaciclib; Ipatasertib; Inavolisib; Ribociclib; Everolimus; Samuraciclib; PH FDC SC; Palbociclib; Atezolizumab,,Hoffmann-La Roche,,316,2021-06-22,2029-05-30,Australia; Israel; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT04802759
NCT04852887,"A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer",Phase 3,Recruiting,Interventional,Stage I Breast Cancer,"Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane); Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)",,NRG Oncology,National Cancer Institute (NCI),1670,2021-06-07,2041-07-05,Canada; Hong Kong; Japan; United States,No,https://clinicaltrials.gov/study/NCT04852887
NCT04862663,"A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)",Phase 3,Recruiting,Interventional,Locally Advanced (Inoperable) or Metastatic Breast Cancer,Capivasertib; Fulvestrant; Palbociclib; Ribociclib; Abemaciclib,,AstraZeneca,,895,2021-05-10,2029-08-14,Argentina; Australia; Belgium; Brazil; Canada; China; Denmark; France; Germany; India; Italy; Japan; Malaysia; Poland; South Korea; Spain; Sweden; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States; Vietnam,No,https://clinicaltrials.gov/study/NCT04862663
NCT05005403,"A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With Azirkitug (ABBV-514) as a Single Agent and in Combination With Budigalimab or Bevacizumab",Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Micro Satellite Stable Colorectal Cancer; Gastric/Esophageal Cancer; High-Grade Serous Ovarian Cancer; Pancreatic Cancer; Triple Negative Breast Cancer,Azirkitug; Budigalimab; Bevacizumab,,AbbVie,,512,2021-11-01,2027-06-05,Israel; Japan; South Korea; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT05005403
NCT05035836,A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC),Phase 2,Recruiting,Interventional,Breast Cancer; HER2-positive,Zanidatamab; Letrozole; Tamoxifen,,M.D. Anderson Cancer Center,Zymeworks BC Inc.,20,2021-11-16,2028-12-29,United States,No,https://clinicaltrials.gov/study/NCT05035836
NCT05053555,High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies,Not Applicable,Recruiting,Interventional,Liver Malignant Tumors; Cholangiocarcinoma Metastatic; Pancreatic Cancer; Melanoma,high dose rate brachytherapy; high dose rate brachytherapy,,M.D. Anderson Cancer Center,,60,2022-04-24,2027-01-31,United States,No,https://clinicaltrials.gov/study/NCT05053555
NCT05083754,"A Randomized, Open-label Pilot Trial to Evaluate the Safety and Efficacy of Carmustine Wafer in Combination With Retifanlimab and Standard Radiation With or Without Temozolomide in Newly-Diagnosed Adult Subjects With Glioblastoma",Phase 1,Recruiting,Interventional,Glioblastoma Multiforme,Retifanlimab; Temozolomide; Radiation Therapy,,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Incyte Corporation,50,2022-08-31,2027-01-05,United States,No,https://clinicaltrials.gov/study/NCT05083754
NCT05086692,"A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,"Advanced Solid Tumor; Unresectable Solid Tumor; Clear Cell Renal Cell Carcinoma; Triple Negative Breast Cancer; Non-Small Cell Lung Cancer Squamous; Non-Small Cell Lung Cancer Non-squamous; Colorectal Cancer (MSI-H); Gastric Cancer; Cervical Cancer; Basal Cell Carcinoma; Bladder Cancer; Merkel Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck; Cutaneous Squamous Cell Carcinoma; Pleural Mesothelioma; Esophageal Cancer; Endometrial Carcinoma; Solid Tumor; Solid Tumor, Adult; MSI-H Solid Malignant Tumor; Cancer With A High Tumor Mutational Burden; Epithelial Ovarian Carcinoma; Primary Peritoneal Cancer; Gastroesophageal Junction (GEJ) Cancer; Acral Melanoma; Mucosal Melanoma; Cutaneous Melanoma; DMMR Solid Malignant Tumor; Fallopian Tube Cancer; Ovarian Cancer; MSI-H Cancer; DMMR Cancer; Pancreas Adenocarcinoma (MSI-H); Skin Cancer; Viral Cancer; Cervical Cancers; Endometrial Cancer",MDNA11; Pembrolizumab (KEYTRUDA®),,"Medicenna Therapeutics, Inc.",Merck Sharp & Dohme LLC,115,2021-08-27,2026-12-30,Australia; Canada; Ireland; Portugal; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT05086692
NCT05095207,"A Multicenter, Phase IB/II Study of Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer",Phase 1/Phase 2,Recruiting,Interventional,Breast Cancer; Metastasis,Abemaciclib; Bicalutamide,,Icahn School of Medicine at Mount Sinai,,42,2021-09-20,2027-12-05,United States,No,https://clinicaltrials.gov/study/NCT05095207
NCT05142592,"A Phase 1/2a, Multi-center, Non-randomized, Open-label, Dose-escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of IPG7236 Administered Orally as a Single Agent in Patients With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Safety Issues; Tolerability; Pharmacokinetics,IPG7236,,"Nanjing Immunophage Biotech Co., Ltd",,196,2021-11-15,2025-12-21,China; United States,No,https://clinicaltrials.gov/study/NCT05142592
NCT05187182,Phase I Trial of CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer,Phase 1,Recruiting,Interventional,Gastric Cancer; Esophageal Cancer; Stomach Cancer; Esophagus Cancer; Gastroesophageal Junction Cancer,CA-4948; Nivolumab; Pembrolizumab; Trastuzumab; mFOLFOX7,,Washington University School of Medicine,"Curis, Inc.; The Foundation for Barnes-Jewish Hospital",42,2023-06-02,2028-06-30,United States,No,https://clinicaltrials.gov/study/NCT05187182
NCT05200559,"The Efficacy of T-regulatory Cell Depletion with E7777 Combined with Immune Checkpoint Inhibitor, Pembrolizumab, in Recurrent or Metastatic Solid Tumors: Phase I/II Study",Phase 1/Phase 2,Recruiting,Interventional,Epithelial Ovarian Cancer,Pembrolizumab; E7777,,"Alexander B Olawaiye, MD","Dr. Reddys Laboratories, SA",70,2022-09-30,2027-12-05,United States,No,https://clinicaltrials.gov/study/NCT05200559
NCT05239546,"Phase II, Single Arm Study of Neoadjuvant Dostarlimab (TSR-042) in Stage II and III Deficient Mismatch Repair Colon Cancers",Phase 2,Recruiting,Interventional,Colon Cancer; dMMR Colorectal Cancer,Dostarlimab,,University of Iowa,,25,2023-03-24,2029-06-30,United States,No,https://clinicaltrials.gov/study/NCT05239546
NCT05253651,An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer,Phase 3,Recruiting,Interventional,Colorectal Neoplasms,tucatinib; trastuzumab; bevacizumab; cetuximab; oxaliplatin; leucovorin; levoleucovorin; fluorouracil,,"Seagen, a wholly owned subsidiary of Pfizer",,400,2022-10-24,2029-07-27,Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; France; Germany; Greece; Ireland; Italy; Japan; Netherlands; Norway; Poland; Portugal; Slovakia; South Korea; Spain; Switzerland; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05253651
NCT05256225,"A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma",Phase 3,Recruiting,Interventional,Endometrial Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Dedifferentiated Carcinoma; Endometrial Endometrioid Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Uterine Corpus Carcinosarcoma,Biospecimen Collection; Carboplatin; Computed Tomography; Echocardiography Test; High-Dose-Rate Vaginal Cuff Brachytherapy; Hyaluronidase-zzxf/Pertuzumab/Trastuzumab; Multigated Acquisition Scan; Paclitaxel; Survey Administration; Trastuzumab/Hyaluronidase-oysk,,National Cancer Institute (NCI),NRG Oncology,360,2022-11-16,2027-10-31,Puerto Rico; South Korea; United States,No,https://clinicaltrials.gov/study/NCT05256225
NCT05277051,"A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Neoplasms,Remzistotug; Dostarlimab; Belrestotug; Nelistotug; GSK5764227,,GlaxoSmithKline,,158,2022-03-22,2027-08-31,Australia; Canada; China; France; Japan; South Korea; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05277051
NCT05438420,"A Phase 1B/2, Open-label Study of Q702 in Combination With Intravenous Pembrolizumab in Patients With Selected Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Esophageal Cancer; Gastric Cancer; Hepatocellular Cancer; Cervical Cancer,Q702; Pembrolizumab,,"Qurient Co., Ltd.",Merck Sharp & Dohme LLC,120,2023-01-12,2026-06-30,South Korea; United States,No,https://clinicaltrials.gov/study/NCT05438420
NCT05464810,"A Randomized Window of Opportunity Study of Preoperative Letrozole and Simvastatin Versus Letrozole Alone in Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer",Early Phase 1,Recruiting,Interventional,Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma; Hormone Receptor-Positive Breast Carcinoma; Invasive Breast Carcinoma,Letrozole; Simvastatin,,Emory University,National Cancer Institute (NCI),40,2022-09-02,2027-04-15,United States,No,https://clinicaltrials.gov/study/NCT05464810
NCT05477576,"Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy",Phase 3,Recruiting,Interventional,GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease; Neuroendocrine Tumors; Carcinoid; Carcinoid Tumor; Pancreatic NET,RYZ101; Everolimus; Sunitinib; Octreotide; Lanreotide,,"RayzeBio, Inc.",,288,2022-03-24,2028-07-05,Belgium; Brazil; Canada; France; Netherlands; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT05477576
NCT05488145,A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy,Not Applicable,Recruiting,Interventional,Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma; Hormone Receptor-Positive Breast Carcinoma,Best Practice; Internet-Based Intervention; Questionnaire Administration; Survey Administration,,Emory University,National Cancer Institute (NCI),30,2023-03-21,2026-06-30,United States,No,https://clinicaltrials.gov/study/NCT05488145
NCT05514717,"A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2",Phase 1,Recruiting,Interventional,HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER2-positive Non-Small Cell Lung Cancer; HER2-positive Colorectal Cancer; HER2-positive Tumors; HER2 Low Breast Cancer,XMT-2056,,Mersana Therapeutics,,162,2023-01-24,2027-04-05,United States,No,https://clinicaltrials.gov/study/NCT05514717
NCT05520099,Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02),,Recruiting,Observational,Immunotherapy; Cancer; Bladder Cancer; Urothelial Carcinoma Bladder; Kidney Cancer; Clear Cell Renal Cell Cancer (ccRCC); Colorectal Cancer; MSI-H Colorectal Cancer; DMMR Colorectal Cancer; Head and Neck Cancer (H&N); Squamous Cell Carcinoma Head and Neck Cancer (HNSCC); Liver Cancer; Hepatocellular Carcinoma (HCC); Lung Cancer (NSCLC); NSCLC (Non-small Cell Lung Cancer); Skin Cancer; Cutaneous Melanoma; Endometrial Cancer; Solid Tumor Cancer,"Core Needle Biopsy, Forceps Biopsy, Punch Biopsy",,Elephas,,416,2023-06-26,2027-01-05,United States,No,https://clinicaltrials.gov/study/NCT05520099
NCT05544929,"A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination With Pembrolizumab in Patients With Select Advanced Cancers",Phase 1,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung; Cutaneous Melanoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Nasopharyngeal Carcinoma; Carcinoma, Thymic; Anal Cancer; Mesothelioma; Esophagogastric Cancer; High Microsatellite Instability Colorectal Carcinoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms",KFA115; pembrolizumab,,Novartis Pharmaceuticals,,180,2022-10-26,2027-09-01,Canada; China; France; Germany; Hong Kong; Italy; Japan; Singapore; South Korea; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT05544929
NCT05559164,STACIE: Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted Therapy,Phase 2,Recruiting,Interventional,Cardiac Toxicity; Early-stage Breast Cancer,Lipitor 40mg Tablet,,"Rutgers, The State University of New Jersey",,60,2022-09-19,2027-03-01,United States,No,https://clinicaltrials.gov/study/NCT05559164
NCT05584670,"A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Solid Tumor,SAR445877; Cetuximab; ADG126; Bevacizumab; Nivolumab; Ipilimumab,,Sanofi,,542,2022-11-29,2028-06-28,Chile; Israel; Netherlands; Spain; United States,No,https://clinicaltrials.gov/study/NCT05584670
NCT05592626,"A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)",Phase 1/Phase 2,Recruiting,Interventional,"Advanced Solid Tumors; Genital Neoplasm, Female; Urogenital Neoplasms; Lung Neoplasm; Neoplasms by Site; Papillomavirus Infection; Epstein-Barr Virus Infections; Carcinoma; Neoplasms; Vulvar Neoplasms; Vulvar Diseases; Abdominal Neoplasm",STAR0602,,"Marengo Therapeutics, Inc.",,365,2023-01-04,2026-10-05,Canada; France; Spain; United States,No,https://clinicaltrials.gov/study/NCT05592626
NCT05636618,A Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors,Phase 1/Phase 2,Recruiting,Interventional,Neuroendocrine Tumors Unresectable; Neuroendocrine Tumor Metastatic; Gastroenteropancreatic Neuroendocrine Tumor; Bronchial Neuroendocrine Tumor; Paraganglioma; Pheochromocytoma,[203Pb]VMT-α-NET; [212Pb]VMT-α-NET,,Perspective Therapeutics,,260,2023-09-27,2029-12-26,United States,No,https://clinicaltrials.gov/study/NCT05636618
NCT05706025,Pilot Study to Evaluate Utility of EnteroTracker® as a Minimally Invasive Sampling Method to Screen for Barrett's Esophagus and Esophageal Cancer,Not Applicable,Enrolling by invitation,Interventional,Barrett Esophagus; Esophageal Cancer,EnteroTracker,,"University of Colorado, Denver",,60,2023-05-31,2029-03-01,United States,No,https://clinicaltrials.gov/study/NCT05706025
NCT05720117,"A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Solid Tumor; Advanced Solid Tumor,PYX-201,,"Pyxis Oncology, Inc",,330,2023-03-14,2027-05-05,Belgium; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05720117
NCT05732623,Diet obEsity sMoking Epigenetics geneTics biomaRkers Physical Activity: An International Multicenter Case-control Study on Endogenous and Exogenous Risk Factors in Early-onset Colorectal Cancer,,Recruiting,Observational,Colorectal Cancer; Early Onset Colorectal Cancer; Diet Habit; Risk Reduction,Semi Quantitative Food Frequency Questionnaire (SQFFQ),,San Raffaele University,"Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; Ospedale Civile Guglielmo da Saliceto, Piacenza, Italy; Centro di Riferimento Oncologico di Aviano, Aviano, Italy; Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari; Gastroenterology Unit, University Hospital of Padova, Padova, Italy; Azienda Ospedaliero-Universitaria Careggi; IRCCS Arcispedale S. Maria Nuova - Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy; Azienda Ospedaliera San Gerardo di Monza, Monza, Italy; Azienda ULSS5 Polesana, Rovigo, Italy; Istituto Tumori Regina Elena - IRCCS IFO, Roma, Italy; University Hospital of Padova, Padova, Italy; IRCCS De Bellis, Castellana Grotte, Italy; University Hospital HELIOS Klinikum Wuppertal, Center for Hereditary Tumors, University of Witten-Herdecke, Wuppertal, Germany; Hospital of the University of Munich (LMU), Campus Großhadern, Munich, Germany; Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain; Helsinki University Hospital, Helsinki, Finland; Oslo University Hospital (OUS), Institute for Cancer Genetics and Informatics Norwegian Radium Hospital, Oslo, Norway; Department of Medicine University of Chicago Medicine, Illinois, USA; University of Colorado Hospital, CO, USA; University of Michigan Ann Arbor, Michigan, USA; Columbia University Irving Medical Center, New York, NY; The James Comprehensive Cancer Center, Columbus, OH, USA; Ohio State University; The Cleveland Clinic; Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia",2300,2022-12-05,2035-01-05,Finland; Germany; Italy; Norway; Spain; United States,No,https://clinicaltrials.gov/study/NCT05732623
NCT05753306,A Phase II Study of Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Gastric Cancer and Limited Peritoneal Metastasis: ROBO-CHIP Trial,Phase 2,Recruiting,Interventional,Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Metastatic Malignant Neoplasm in the Peritoneum,Cisplatin; Computed Tomography; Gastrectomy; Magnetic Resonance Imaging; Positron Emission Tomography; Questionnaire Administration; Paclitaxel; Hyperthermic Intraperitoneal Chemotherapy,,Mayo Clinic,,40,2023-04-20,2028-03-31,United States,No,https://clinicaltrials.gov/study/NCT05753306
NCT05802056,COordinated Nivolumab and IntraperiToneal IL-2 for Gastric CanceR With PeritOneaL Metastasis (CONTROL) Phase 1b Pilot Study,Phase 1,Recruiting,Interventional,Clinical Stage IV Gastric Cancer AJCC v8; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Metastatic Gastric Carcinoma; Metastatic Malignant Neoplasm in the Peritoneum,Aldesleukin; Biopsy; Biospecimen Collection; Computed Tomography; Diagnostic Laparoscopy; Fluorouracil; Leucovorin Calcium; Magnetic Resonance Imaging; Nivolumab; Oxaliplatin; Positron Emission Tomography,,Mayo Clinic,,15,2023-11-29,2030-04-15,United States,No,https://clinicaltrials.gov/study/NCT05802056
NCT05838768,"An Open-label, Multi-center Phase I/Ib Dose Finding and Expansion Study of HRO761 as Single Agent and in Combinations in Patients With Microsatellite Instability-High or Mismatch Repair Deficient Advanced Solid Tumors.",Phase 1,Recruiting,Interventional,"MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers",HRO761; pembrolizumab; irinotecan,,Novartis Pharmaceuticals,,327,2023-06-27,2029-05-30,Belgium; China; France; Germany; Israel; Italy; Japan; Norway; Singapore; South Korea; Spain; Sweden; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05838768
NCT05855200,"A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer",Phase 3,Recruiting,Interventional,"Colonic Neoplasms; Neoplasms, Colon",Dostarlimab; CAPEOX; FOLFOX,,GlaxoSmithKline,,811,2023-08-01,2031-03-27,Argentina; Australia; Belgium; Brazil; Canada; China; Estonia; Finland; France; Germany; Greece; Italy; Japan; Mexico; Netherlands; Norway; Panama; Portugal; South Korea; Spain; Sweden; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05855200
NCT05879926,"A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)",Phase 3,Recruiting,Interventional,Breast Cancer,Ovarian Function Suppression + Aromatase Inhibitor; Adjuvant Chemotherapy + Ovarian Function Suppression,,NRG Oncology,National Cancer Institute (NCI),3960,2023-08-31,2034-07-05,Canada; Colombia; Japan; Mexico; Peru; Puerto Rico; United States; Uruguay,No,https://clinicaltrials.gov/study/NCT05879926
NCT05889806,AUD Biomarkers Study (Proteomic and Genomic Analysis of Biospecimens Involved in Diseases and Healthy Populations),,Enrolling by invitation,Observational,Oncology; Hematologic Malignancy; Gastro-Intestinal Disorder; Autoimmune Diseases; Pregnancy Related; Infectious Disease; Cardiovascular Diseases; Genitourinary Disease; Renal Disease,Observational Study Only. NO Intervention.,,Audubon Bioscience,,10000,2023-05-10,2043-06-10,United States,No,https://clinicaltrials.gov/study/NCT05889806
NCT05894239,"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer",Phase 3,Recruiting,Interventional,Metastatic Breast Cancer,Inavolisib; Phesgo; Placebo; Taxane-based Chemotherapy; Optional Endocrine Therapy of Investigator's Choice,,Hoffmann-La Roche,,230,2023-09-08,2032-12-28,Argentina; Australia; Belgium; Brazil; Canada; China; Colombia; Finland; France; Germany; Hong Kong; India; Italy; Jordan; Kenya; Mexico; Oman; Poland; Singapore; South Africa; South Korea; Spain; Taiwan; Tunisia; Turkey (Türkiye); Uganda; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05894239
NCT05919264,A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors,Phase 1/Phase 2,Recruiting,Interventional,Cancer; Colorectal Cancer; Solid Tumor; Locally Advanced Solid Tumor; Metastatic Cancer; WNT Pathway; β-catenin; Beta-catenin; Adenomatous Polyposis Coli; APC; HCC; Desmoid; Microsatellite Stable Colorectal Cancer; Metastatic Castration-resistant Prostate Cancer; FAP; Endometrial Carcinoma; Prostate Cancer; Microsatellite Instability-High Colorectal Cancer; CTNNB1; Adamantinomatous Craniopharyngioma,FOG-001; mFOLFOX-6; Nivolumab; Trifluridine/tipiracil; Bevacizumab,,"Parabilis Medicines, Inc.",,575,2023-05-23,2027-08-31,United States,No,https://clinicaltrials.gov/study/NCT05919264
NCT05959291,Free-HER: Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer,Not Applicable,Recruiting,Interventional,HER2-positive Metastatic Breast Cancer; Stage IV Breast Cancer,Discontinuation of Anti-HER-2 Maintenance Treatment,,University of Miami,,20,2023-07-17,2029-07-31,United States,No,https://clinicaltrials.gov/study/NCT05959291
NCT05977036,BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer,Not Applicable,Recruiting,Interventional,Metastatic Breast Cancer; Unresectable Breast Cancer,DiviTum® TKa assay; CDK4/6 + Endocrine therapy,,Washington University School of Medicine,Biovica,65,2024-09-25,2034-09-30,United States,No,https://clinicaltrials.gov/study/NCT05977036
NCT05985148,A Phase I Dose Escalation Trial for Treatment of Chronic Thoracoabdominal Wall Pain Through Ablation of the Dorsal Spinal Nerve Using Single-Fraction Stereotactic Radiosurgery,Phase 1,Recruiting,Interventional,Thoracoabdominal Wall Pain; Secondary to Parietal Pleura or Parietal Peritoneum Disease,Single-fraction stereotactic radiosurgery (SRS),,Memorial Sloan Kettering Cancer Center,Varian Medical Systems,18,2023-08-02,2028-08-05,United States,No,https://clinicaltrials.gov/study/NCT05985148
NCT05986279,Improving Psychological and Vestibular Health Using a Novel Intervention: The Making Informed Decisions in Gaze and Postural Stability (MINDGAPS) System,Not Applicable,Recruiting,Interventional,Vestibular Hypofunction,Rehab,,University of Montana,"United States Naval Medical Center, San Diego; Congressionally Directed Medical Research Programs",500,2023-08-30,2027-09-29,United States,No,https://clinicaltrials.gov/study/NCT05986279
NCT05986604,"NIA_Improving Sleep and Circadian Functioning, Daytime Functioning, and Well-being for Midlife and Older Adults by Improving Patient Memory for a Transdiagnostic Sleep and Circadian Treatment",Not Applicable,Recruiting,Interventional,Sleep Disorder; Circadian Dysregulation; Memory Impairment,Memory Support Intervention; Transdiagnostic Intervention for Sleep and Circadian Dysfunction,,"University of California, Berkeley",,178,2024-01-04,2028-07-28,United States,No,https://clinicaltrials.gov/study/NCT05986604
NCT05996107,"A Phase 1B Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, Node Positive, HR+/HER2- Breast Cancer",Phase 1,Recruiting,Interventional,Breast Cancer,Ribociclib; Postoperative Radiation Therapy,,University of Michigan Rogel Cancer Center,,30,2024-02-27,2030-06-05,United States,No,https://clinicaltrials.gov/study/NCT05996107
NCT06006923,Randomized Trial of Regorafenib in Combination With Pembrolizumab or Pembrolizumab Monotherapy With an Efficacy Lead-in of Regorafenib and Pembrolizumab for Patients With MSI-H Colorectal Cancer,Phase 2,Recruiting,Interventional,MSI-H Colorectal Cancer,Regorafenib; Pembrolizumab,,Anwaar Saeed,Bayer,154,2024-06-26,2029-06-05,United States,No,https://clinicaltrials.gov/study/NCT06006923
NCT06047379,"An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors.",Phase 1/Phase 2,Recruiting,Interventional,"Diffuse Astrocytoma, IDH-Mutant; Glioblastoma, IDH-wildtype; Brain Metastases, Adult; Cervical Cancer; Colorectal Cancer; Esophageal Cancer; Esophageal Squamous Cell Carcinoma; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Head and Neck Squamous Cell Carcinoma; Melanoma; Merkel Cell Carcinoma; Microsatellite Instability-High Solid Malignant Tumor; Mismatch Repair Deficient Solid Malignant Tumor; Microsatellite Instability-High Colorectal Cancer; Mismatch Repair Deficient Colorectal Cancer; Non-small Cell Lung Cancer; Renal Cell Carcinoma; Small Cell Lung Cancer; Squamous Cell Carcinoma; Urothelial Carcinoma",NEO212 Oral Capsule; Ipilimumab; Pembrolizumab; Nivolumab; Regorafenib; Carboplatin; Paclitaxel; FOLFIRI Protocol; Bevacizumab,,"Neonc Technologies, Inc.",,134,2023-11-01,2027-08-31,United States,No,https://clinicaltrials.gov/study/NCT06047379
NCT06062498,"Randomized Phase II Study of Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor (Palbociclib, Abemaciclib, or Ribociclib) in Patients With ER+/HER2- Advanced or Metastatic Breast Cancer With Prior Exposure to a CKD4/6 Inhibitor",Phase 2,Recruiting,Interventional,Estrogen-receptor-positive Breast Cancer; HER2/Neu-Negative Breast Cancer; Advanced Breast Cancerv; Metastatic Breast Cancer,"elacestrant, palbociclib, abemaciclib, ribociclib",,Northwestern University,National Cancer Institute (NCI),174,2023-09-29,2027-07-01,United States,No,https://clinicaltrials.gov/study/NCT06062498
NCT06084481,A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications,Phase 1,Recruiting,Interventional,Hepatocellular Carcinoma; Pancreatic Ductal Adenocarcinoma; Biliary Tract Cancers; Esophageal Squamous Cell Carcinoma; Triple Negative Breast Cancer; Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer; Head and Neck Squamous-Cell Carcinoma; Platinum Resistant High Grade Epithelial Ovarian Cancer,ABBV-400; Itraconazole (ITZ),,AbbVie,,285,2023-11-09,2026-07-05,Australia; Israel; Japan; Puerto Rico; South Korea; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06084481
NCT06084780,Prospective Case Series of Intestinal and Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE),Phase 2,Not yet recruiting,Interventional,Secondary Malignant Neoplasm of Retroperitoneum; Secondary Malignant Neoplasm of Peritoneum; Pseudomyxoma Peritonei,"Intestinal, Multivisceral or Modified Multivisceral Transplantation; Alemtuzumab; Tacrolimus; Sirolimus",,Case Comprehensive Cancer Center,,20,2025-12-05,2025-12-31,United States,No,https://clinicaltrials.gov/study/NCT06084780
NCT06126276,"A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial",Phase 2,Recruiting,Interventional,Malignant Female Reproductive System Neoplasm; Malignant Solid Neoplasm; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm,Biopsy Procedure; Biospecimen Collection; Computed Tomography; Echocardiography Test; Magnetic Resonance Imaging; Multigated Acquisition Scan; Neratinib Maleate; Palbociclib,,National Cancer Institute (NCI),,70,2024-05-07,2027-02-20,United States,No,https://clinicaltrials.gov/study/NCT06126276
NCT06127979,"Differential Changes in Ki67 Between Carriers and Noncarriers of BRCA2 Mutations With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-negative Breast Cancer Treated With Preoperative Endocrine Therapy",Not Applicable,Recruiting,Interventional,Breast Cancer,core needle biopsy; blood draw,,Memorial Sloan Kettering Cancer Center,,42,2023-11-06,2028-11-05,United States,No,https://clinicaltrials.gov/study/NCT06127979
NCT06138808,Prognostic Value of the 5-SENSE Score to Predict Focality of the Seizure-onset Zone as Assessed by Stereo-electroencephalography - a Prospective Multicenter Validation Study,,Enrolling by invitation,Observational,Epilepsy Intractable,Stereoelectroencephalography (SEEG),,Duke University,Christian Doppler University Hospital,400,2024-01-09,2025-11-05,Australia; Austria; Canada; Czechia; Denmark; France; Germany; Japan; Romania; Spain; Switzerland; United States,No,https://clinicaltrials.gov/study/NCT06138808
NCT06188585,Randomized Controlled Multi-Center Non-Inferiority Trial of UI-EWD (Nexpowder™) vs. Conventional Treatment as First-Line Endoscopic Therapy for Patients With High-Risk Nonvariceal Upper Gastrointestinal Bleeding (TREET),Not Applicable,Recruiting,Interventional,Acute Gastrointestinal Bleeding,UI-EWD; Conventional therapy,,Medtronic - MITG,North American Science Associates Ltd.,278,2024-06-21,2026-08-05,Canada; Denmark; France; Israel; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06188585
NCT06219941,"A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)",Phase 2,Recruiting,Interventional,Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer; Pancreatic Ductal Adenocarcinoma,AZD0901; 5-Fluorouracil; Leucovorin; l-leucovorin; Irinotecan; Nanoliposomal Irinotecan; Gemcitabine,,AstraZeneca,,190,2023-12-13,2026-12-31,Australia; Canada; China; Georgia; Japan; Malaysia; Moldova; Poland; Singapore; South Korea; Spain; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06219941
NCT06224673,Phase II Open-label Study of ARX788 (Anti-HER2 Antibody Drug Conjugate (ADC)) for Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer,Phase 2,Not yet recruiting,Interventional,HER2 Low Breast Carcinoma; Triple Negative Breast Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive Breast Carcinoma,ARX788; Computed Tomography (CT); Biospecimen Collection; Amiloride,,"Laura Huppert, MD, BA","Ambrx, Inc.",36,2026-01-15,2029-03-31,United States,No,https://clinicaltrials.gov/study/NCT06224673
NCT06253871,A Phase 1/1b Study of IAM1363 in Patients With Advanced Cancers Harboring HER2 Alterations,Phase 1,Recruiting,Interventional,HER2 Mutation-Related Tumors; HER2; HER2-positive Breast Cancer; HER2 + Breast Cancer; Brain Metastases From Solid Tumors; Brain Metastases From HER2 and Breast Cancer; CNS Metastases; HER2-Positive Solid Tumors; NSCLC (Non-small Cell Lung Cancer); HER2-positive Bladder Cancer; HER2-positive Colorectal Cancer; HER2 + Gastric Cancer; HER2-positive Gastroesophageal Cancer,IAM1363,,"Iambic Therapeutics, Inc",,243,2024-03-25,2028-03-05,France; Ireland; Netherlands; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT06253871
NCT06257264,"A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Breast Cancer; Small Cell Lung Cancer; Ovarian Cancer; Gastric Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Advanced Solid Tumor; Endometrial Cancer; Prostate Cancer; TNBC - Triple-Negative Breast Cancer; GastroEsophageal Cancer; Bladder Cancer,BG-68501; Fulvestrant; BGB-43395,,BeiGene,,258,2024-03-11,2028-07-05,Australia; China; Israel; Moldova; New Zealand; United States,No,https://clinicaltrials.gov/study/NCT06257264
NCT06348134,Assessing the Efficacy and Safety of Optimal Neoadjuvant to Adjuvant Anti-HER2- Based Therapy in Nigerian Women With HER2+ Breast Cancer,Phase 2,Not yet recruiting,Interventional,Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; HER2-positive Breast Cancer; Breast Cancer,Trastuzumab emtansine; Pertuzumab Injection; Docetaxel; Tamoxifen; Letrozole; Goserelin,,University of Chicago,,74,2026-01-01,2036-07-01,Nigeria; United States,No,https://clinicaltrials.gov/study/NCT06348134
NCT06361940,Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer (MAPPER),Phase 2,Recruiting,Interventional,Breast Cancer,Aromatase inhibitors or tamoxifen,,Medical College of Wisconsin,,100,2024-09-30,2029-12-05,United States,No,https://clinicaltrials.gov/study/NCT06361940
NCT06362369,"A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy in Patients With Locally Advanced or Metastatic Cancers Following One or More Prior Therapies",Phase 1/Phase 2,Recruiting,Interventional,Advanced Cancer; Advanced Solid Tumor; Melanoma; Metastasis; Pleural Mesothelioma; Renal Cell Carcinoma; MSI-High; Mismatch Repair Deficiency; Colorectal Cancer; Hepatocellular Carcinoma; Hepatocellular Cancer; Renal Cell Cancer; Kidney Cancer; Skin Cancer; Non Small Cell Lung Cancer; NSCLC; Anaplastic Lymphoma Kinase Genomic Tumor Aberrations; ALK Genomic Tumor Aberrations,Alintegimod; Ipilimumab; Nivolumab,,"7 Hills Pharma, LLC",,126,2024-08-23,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT06362369
NCT06374459,A Phase Ib/II Trial of Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis,Phase 1/Phase 2,Recruiting,Interventional,Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer,Zumsemetinib; Capecitabine; Zoledronic acid; Denosumab,,Washington University School of Medicine,"United States Department of Defense; Aclaris Therapeutics, Inc.",152,2025-01-30,2032-05-31,United States,No,https://clinicaltrials.gov/study/NCT06374459
NCT06439693,"A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer: The SAPPHO Study",Phase 2,Recruiting,Interventional,Breast Cancer Female; Breast Cancer; Breast Cancer Metastatic; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Stage IV Breast Cancer,Nab-Paclitaxel; Paclitaxel; Docetaxel; Phesgo; T-DM1; Pertuzumab; Trastuzumab Deruxtecan; Trastuzumab Subcutaneous Subcutaneous; Tucatinib; Trastuzumab,,Dana-Farber Cancer Institute,Translational Breast Cancer Research Consortium; Johns Hopkins University,72,2024-08-08,2033-03-30,United States,No,https://clinicaltrials.gov/study/NCT06439693
NCT06445972,"A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D",Phase 1/Phase 2,Recruiting,Interventional,Gastroesophageal Junction; Gastroesophageal Adenocarcinoma; Esophageal Neoplasms; Esophageal Cancer,Ramucirumab; Paclitaxel; Sacituzumab Tirumotecan; Rescue Medications; HER3-DXd,,Merck Sharp & Dohme LLC,Daiichi Sankyo,210,2024-08-07,2028-10-27,Brazil; Chile; China; France; Germany; Italy; Norway; South Korea; Switzerland; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06445972
NCT06503146,18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection,Phase 2,Recruiting,Interventional,Sarcoma; Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC); Mesothelioma; Pheochromocytoma/Paraganglioma (PPGL); Pancreatic Ductal Adenocarcinoma; Ovarian Cancer; Hepatocellular Carcinoma; Gastric Cancer; Cholangiocarcinoma; Bladder Cancer,[18F]FAPI-74; [18F]FDG,,National Cancer Institute (NCI),,320,2025-09-09,2030-06-01,United States,No,https://clinicaltrials.gov/study/NCT06503146
NCT06551116,QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer,,Recruiting,Observational,HER2-positive Metastatic Breast Cancer,CE-10-IVD,,Abramson Cancer Center at Penn Medicine,Translational Breast Cancer Research Consortium; Danaher Inc.,200,2024-10-10,2029-09-01,United States,No,https://clinicaltrials.gov/study/NCT06551116
NCT06552260,A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma,Early Phase 1,Recruiting,Interventional,Glioblastoma; Recurrent Glioblastoma; Brain Tumor,Troriluzole,,Ugonma Chukwueke,"National Institutes of Health (NIH); Biohaven Pharmaceuticals, Inc.",27,2025-02-19,2027-08-01,United States,No,https://clinicaltrials.gov/study/NCT06552260
NCT06625515,"A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-559, an Oral Inhibitor of the Helicase DHX9, in Patients With Locally Advanced or Metastatic Solid Tumors and Molecularly Defined Cancers",Phase 1,Recruiting,Interventional,Advanced Solid Tumors; Breast Cancer Recurrent; Colorectal Cancer Metastatic; Colon Cancer; Rectal Adenocarcinoma; Endometrial Cancer,ATX-559,,Accent Therapeutics,,100,2024-10-11,2027-02-05,United States,No,https://clinicaltrials.gov/study/NCT06625515
NCT06671912,"LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients With Molecular Low-Risk Early-Stage Breast Cancer",Phase 3,Recruiting,Interventional,Anatomic Stage 0 Breast Cancer AJCC v8; Anatomic Stage 1 Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Estrogen Receptor-Positive Breast Carcinoma; HER2-Negative Breast Carcinoma,Anastrozole; Letrozole; Exemestane; Tamoxifen; Mammogram; Magnetic Resonance Imaging; Dual X-ray Absorptiometry; Biospecimen Collection; Questionnaire Administration,,Alliance for Clinical Trials in Oncology,National Cancer Institute (NCI),1156,2025-02-19,2031-11-30,Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT06671912
NCT06691035,Immunologic Targeting of Native and Mutated ESR1 Receptor for Treatment of Hormone Receptor Expressing Metastatic Breast Cancer,Phase 1,Recruiting,Interventional,Breast Cancer Metastatic Breast Cancer; HER2-negative Breast Cancer,Elacestrant; DC1 native/mutated ESR1,,H. Lee Moffitt Cancer Center and Research Institute,The V Foundation for Cancer Research,18,2024-11-04,2027-11-05,United States,No,https://clinicaltrials.gov/study/NCT06691035
NCT06695845,"A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)",Phase 2,Recruiting,Interventional,Breast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endometrial Cancer; Non-small Cell Lung Cancer; Ovarian Cancer; Urothelial Carcinoma; Salivary Gland Cancer; Pancreatic Cancer; HER-2 Protein Overexpression,Zanidatamab,,Jazz Pharmaceuticals,Jazz Pharmaceuticals Ireland Limited,200,2025-01-14,2027-12-31,South Korea; United States,No,https://clinicaltrials.gov/study/NCT06695845
NCT06710756,"A Phase I/IIa Image-Guided, Alpha-Particle Therapy Study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in Patients With Solid Tumors That Are Known to be Fibroblast Activation Protein (FAP)-Positive",Phase 1/Phase 2,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma; Gastric Cancer; Esophageal Cancer; Colorectal Cancer; Ovarian Cancer; Head and Neck Cancer; Sarcoma; Mesothelioma,[203Pb]Pb-PSV359; [212Pb]Pb-PSV359,,Perspective Therapeutics,,112,2025-04-28,2032-05-28,United States,No,https://clinicaltrials.gov/study/NCT06710756
NCT06710847,"A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors (SYLVER)",Phase 1/Phase 2,Recruiting,Interventional,"Neoplasms, Colorectal; Solid Tumor; Colon Cancer; Rectal Cancer; Endometrial Cancer",GSK4418959; PD-1 inhibitor,,GlaxoSmithKline,IDEAYA Biosciences,73,2024-12-13,2028-06-16,Australia; Japan; South Korea; United States,No,https://clinicaltrials.gov/study/NCT06710847
NCT06726148,"An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors,ECI830; ribociclib; fulvestrant,,Novartis Pharmaceuticals,,280,2025-04-03,2028-09-25,Australia; Canada; Czechia; Denmark; France; Germany; Israel; Italy; Japan; Singapore; South Korea; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06726148
NCT06731998,"Evaluating Optimal Perioperative Pain Management: A Prospective Randomized Control Trial of Laparoscopic Transversus Abdominis Plane Block With Local Anesthetic, Laparoscopic Transversus Abdominis Plane Block Alone, and Local Anesthetic Alone in Minimally Invasive Oncologic Surgery",Not Applicable,Recruiting,Interventional,"Oncologic Surgery; Cancer; Cancer Surgery; Hepatic Cancer; Gastric (Cardia, Body) Cancer; Biliary Tract Cancer; Pancreatic Cancer Resectable; Gynecologic Cancers; Gastrointestinal Cancers; Colorectal Cancer; Minimally Invasive Surgical Procedures",Local Anesthesia; Laparoscopic Transversus Abdominis Plane block,,Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute),,48,2025-02-05,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT06731998
NCT06760637,"AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)",Phase 3,Recruiting,Interventional,Breast Cancer,PF-07220060; letrozole; abemaciclib; palbociclib; ribociclib,,Pfizer,,1020,2025-01-06,2037-12-29,Argentina; Australia; Belgium; Brazil; Bulgaria; Canada; China; Czechia; Denmark; Finland; France; Germany; Greece; Hungary; India; Ireland; Israel; Italy; Japan; Mexico; Netherlands; Poland; Slovakia; South Korea; Spain; Sweden; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06760637
NCT06790693,"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer",Phase 3,Recruiting,Interventional,Breast Cancer,Inavolisib; Placebo; CDK4/6i; Letrozole,,Hoffmann-La Roche,,450,2025-04-09,2032-05-30,Argentina; Australia; Brazil; Canada; China; France; Germany; Italy; Mexico; Poland; Puerto Rico; South Africa; South Korea; Spain; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06790693
NCT06807437,A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula,Phase 3,Recruiting,Interventional,Pancreatic Carcinoma; Pancreatic Neoplasm,Biospecimen Collection; Distal Pancreatectomy; Lanreotide; Questionnaire Administration; Saline,,SWOG Cancer Research Network,National Cancer Institute (NCI),274,2025-05-09,2027-11-01,United States,No,https://clinicaltrials.gov/study/NCT06807437
